Unmet needs in adults with T2D receiving premixed insulin
Suboptimal glycemic target achievement is common in people with T2D
In a meta-analysis of 24 studies across 20 countries: the proportion of people achieving HbA1c targets was 43%.1
According to the IDMPS:<50% of participants achieved a glycaemic goal of HbA1c <7% in LMICs2
Real-world evidence shows poor glycemic control with premix
<20%: UK THIN: <20% achieved HbA1c <7.5% 24 months after initiating with premix insulin3
∼20%: IDMPS: ~20% on premix insulin reached HbA1c <7% in LMICs4
>28%: CoDiC: >28% had their HbA1c >8% for 17 months after switching from BI to premix insulin5
Many people with T2D eventually require injectable therapy.6-8
Globally, 30% of people with T2D use premix insulin9, but this is associated with:
Greater bodyweight gain vs BI:10
Premix insulin: +0.8 kg to +5.4 kg
BI: +0.1 kg to +3.5 kg
Increased hypoglycemia risk vs BI10
Premix insulin: 3.4 to 8.2 events PPY
BI: 0.7 to 5.4 events PPY
T2D, type 2 diabetes BI, basal insulin; IDMPS, International Diabetes Management Practices Study, LMIC, low-to-middle income country; THIN, The Health Improvement Network.BiAsp; CoDiC, Computerized Diabetes Care, Japan Diabetes Clinical Data Management Study Group; BI, basal insulin; PPY, per-patient-year
Khunti K, et al. Diabet Res Clin Pract 2018;137:137-148.
Aschner P, et al. Diabetologia. 2020;63(4):711-721.
Jude EB, et al. Diabet Obes Metab 2020. doi: 10.1111/dom.14298.
Ramachandran A et al. Diabetologia 2019;62:S425.
Satoh J et al. PLoS One 2018;13:e0198160.
Davies MJ, et al. Diabetes Care 2018;41(12):2669-2701.
American Diabetes Association. Diabetes Care 2021;44(Supplement 1):S111-S124.
National Institute for Clinical Excellence (NICE). Available from https://www.nice.org.uk/guidance/ng28/resources/-type-2-diabetes-in-adults-management-pdf-1837338615493 [Accessed 30 June 2020].
Polinski JM, et al. BMC endocrine disorders 2015;15:46. 10. Ilag LL, et al. Clinical Ther 2007;29 Spec No:1254-1270.
New technologies in Type 2 Diabetes management and future opportunities to improve clinical outcomes
This session emphasizes that new technology in Diabetes management not only can overcome common barriers in achieving glycemic control in people with T2D but also may facilitate more effective and efficient Diabetes care.
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.
.jpg/jcr:content/Bright%20study%20(1).jpg)
